HOWL Biotech Catalysts

Werewolf Therapeutics, Inc.

Fintel Biotech Intelligence

HOWL biotech catalysts

Clinical-trial, drug-development and regulatory milestones for Werewolf Therapeutics, Inc..

HOWL (US) TRIAL_COMPLETION 2028-08-01 to 2028-08-31
Company
Werewolf Therapeutics, Inc.
Drug or asset
WTX-330
Indication
Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Phase
Phase 1b/2
Status
upcoming
How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista